Jim Arthurs, David Keren, Sofia Merajver, Amanda Cook and Lynn McCain
On Thursday, December 20, 2018, at 3:30 pm, the founders of InheRET, Inc., participated in the bell ringing ceremony at the University of Michigan’s Technology Transfer office. The event signaled the formal licensing of technology developed at the University of Michigan to the spin-off corporation.
InheRET, Inc., developed jointly by the Department of Pathology and the Department of Internal Medicine faculty and staff, has produced an online family health history questionnaire. It interprets patient-entered data against best practice guidelines to determine if patients are at increased risk for hereditary disease. This program is in pilot testing, funded by Blue Cross Blue Shield Foundation, at three University of Michigan clinics: Dexter Family Medicine, University Health Service, and the Breast and Ovarian Cancer Risk Evaluation Clinic. More than 30% of primary care patients taking the questionnaire have been identified as at increased risk for hereditary cancers. These patients, who were not previously identified in the primary care setting, are now eligible for further evaluation by genetics specialists. They can discuss preventive options with their healthcare providers and can reduce their cancer risk by as much as 95%.
The InheRET team represents the wide spectrum of expertise and experience necessary for success:
Pilot testing will continue through the remainder of 2018 and into early 2019. A commercial launch of the product is expected during the first quarter of 2019. InheRET is currently seeking beta testing sites as well as Business and Scientific Advisory Board members. For more information, go to https://www.InheRET.com, email info@InheRET.com, or call 866-464-3738.